Ironwood Pharmaceuticals (IRWD) has been under a strong bear grip, hence the stock is down -3.34% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 1.63% in the past 1 week. The stock has risen by 0.96% in the past week indicating that the buyers are active at lower levels, but the stock is down -3.54% in the past 4 weeks.
Company shares have received an average consensus rating of Hold for the current week The stock has recorded a twenty day Moving Average of 0.26% and the fifty day Moving Average is 1.93%. Ironwood Pharmaceuticals, Inc. is up 10.1% in the last three month period. Year-to-Date the stock performance stands at 17.6%.
Ironwood Pharmaceuticals (IRWD) : 7 investment research analysts covering Ironwood Pharmaceuticals (IRWD) have an average price target of $14.86 for the near short term. The highest target price given by the Brokerage Firm to the stock is $24 and the lowest target is $10 for the short term. Analysts expect the variance to be within $4.6 of the average price.
Ironwood Pharmaceuticals (NASDAQ:IRWD): stock turned positive on Friday. Though the stock opened at $13.49, the bulls momentum made the stock top out at $13.82 level for the day. The stock recorded a low of $13.39 and closed the trading day at $13.63, in the green by 0.96%. The total traded volume for the day was 850,972. The stock had closed at $13.5 in the previous days trading.
Ironwood Pharmaceuticals, Inc. is a pharmaceutical company. The Company has a product, linaclotide, which is available in the United States and Mexico under the brand name LINZESS, and is available in European countries and Canada under the brand name CONSTELLA. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. The Company in collaboration with Astellas Pharma Inc. (Astellas) is developing linaclotide for the treatment of patients with IBS-C.